Results 81 to 90 of about 8,627 (176)

Dabigatran etexilate: a direct thrombin inhibitor

Italian Journal of Medicine, 2013
BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. Unlike heparin, they directly interact with thrombin and block fibrinogen binding.
M. Dugnani
doaj   +1 more source

The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice. [PDF]

Pharmaceuticals (Basel), 2023
Kadoglou NP, Stasinopoulou M, Gkougkoudi E, Christodoulou E, Kostomitsopoulos N, Valsami G.   +5 more
europepmc   +1 more source

DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?

Евразийский Кардиологический Журнал, 2017
The article discusses stroke prevention in elderly patients with atrial fibrillation. The principles of choosing anticoagulant therapy in this group of patients are discussed.
O. N. Tkacheva, N. M. Vorobyeva
doaj   +1 more source

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation. [PDF]

Front Cardiovasc Med, 2022
Liu YO, Xie QF, Liu ZY, Wang Z, Mu GY, Zhang YT, Zhao ZN, Yuan DD, Guo LP, Wang N, Xiang J, Song HT, Jiang J, Xiang Q, Cui YM.   +14 more
europepmc   +1 more source

Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease

, 2011
Objective: To evaluate the efficacy and safety of dabigatran etexilate, approved by the Food and Drug Administration (FDA) in October 2010 for the prevention of cardioembolic stroke in patients with atrial fibrillation; potential off-label use is ...
John G Gums, Steven M Smith, Jessica A Bovio   +2 more
core   +1 more source

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +1 more source

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

Medicina, 2019
Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins ...
Gintautas Gumbrevičius, Gytė Damulevičienė, Vaidotas Galaunė, Milda Gumbrevičiūtė   +3 more
doaj   +1 more source

Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation : the IDEA Study [PDF]

, 2019
BACKGROUND AND OBJECTIVES: Warfarin-related nephropathy is an unexplained acute kidney injury, and may occur in patients with supratherapeutic INR, in the absence of overt bleeding.
Polo Friz, Hernan, Crippa, Matteo, Orenti, Annalisa, Tramacere, Pierluigi, Molteni, Mauro, Cimminiello, Claudio, Marano, Giuseppe, Menghini, Anna, Boracchi, Patrizia   +8 more
core   +1 more source

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults. [PDF]

Eur J Pharm Sci, 2023
Sia JEV, Lai X, Wu X, Zhang F, Li H, Cui C, Liu D.   +6 more
europepmc   +1 more source

Use of oral anticoagulants after intramedullary nailing of femur and tibial fractures in trauma department

Travmatologiâ i Ortopediâ Rossii, 2016
The authors evaluated of the effectiveness of new oral anticoagulants in patients with diaphyseal fractures of the femur and tibia.We analyzed the effectiveness of thromboprophylaxis in 85 patients with diaphyseal fractures of the femur and tibia in the ...
A. K. Dulaev, A. N. Tsed, I. G. Dzhusoev
doaj